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Abstract: A new method using a magnetic nanoparticle-based colorimetric biosensing assay (NCBA)
was compared with sputum smear microscopy (SSM) for the detection of pulmonary tuberculosis (PTB)
in sputum samples. Studies were made to compare the NCBA against SSM using sputum samples
collected from PTB patients prior to receiving treatment. Experiments were also conducted to determine
the appropriate concentration of glycan-functionalized magnetic nanoparticles (GMNP) used in the
NCBA and to evaluate the optimal digestion/decontamination solution to increase the extraction,
concentration and detection of acid-fast bacilli (AFB). The optimized NCBA consisted of a 1:1 mixture
of 0.4% NaOH and 4% N-acetyl-L-cysteine (NALC) to homogenize the sputum sample. Additionally,
10 mg/mL of GMNP was added to isolate and concentrate the AFB. All TB positive sputum samples
were identified with an increased AFB count of 47% compared to SSM, demonstrating GMNP’s ability
to extract and concentrate AFB. Results showed that NCBA increased AFB count compared to SSM,
improving the grade from “1+” (in SSM) to “2+”. Extending the finding to paucibacillary cases, there
is the likelihood of a “scant” grade to become “1+”. The assay uses a simple magnet and only costs
$0.10/test. NCBA has great potential application in TB control programs.
Keywords: Mycobacterium tuberculosis; increased sensitivity; sputum smear microscopy; TB detection;
nanotechnology; infectious disease
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1. Introduction
One third of the world’s population carries an asymptomatic infection from Mycobacterium
tuberculosis (Mtb). In 2017, 10.4 million people fell ill with tuberculosis (TB), and 1.6 million died from
the disease (including 0.4 million among people with HIV) [1]. Cost, technical limitations and lack of
resources make the diagnosis of TB difficult in developing countries, where the majority of cases occur.
The primary method to diagnose TB in most low and middle income countries is sputum smear
microscopy (SSM), using the Ziehl-Neelsen (ZN) staining technique [2]. SSM is highly specific for
Mtb and can identify the most infectious patients in areas where there is a high TB prevalence [2].
Although this test is easy to perform, inexpensive, provides rapid results and does not require complex
laboratory equipment, it has considerable drawbacks [3]. The clinical sensitivity of this test is highly
variable (20–80%) with much lower sensitivity in paucibacillary cases, such as in immunocompromised
or pediatric patients where the bacterial load is usually fewer than 5,000–10,000 acid-fast bacilli (AFB)
per milliliter of sputum sample [2–4].
The World Health Organization endorses the Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA)
real-time PCR platform to diagnose TB, primarily because it can identify rifampicin resistance in
a short amount of time (120 min) [5]. However, its use is limited due to the high cost (instrument,
cartridges and laboratory requirements) [6]. Additionally, reports have indicated that it can provide
false-positive results [7,8].
Recent advances in nanotechnology have enabled the development of new diagnostic platforms
aimed at more sensitive and faster pathogen detection [9–14]. However, they are designed for
operation in environments with fully supported infrastructure [10–14]. Simple and low-cost
nanotechnology-based TB diagnostics are still needed, where there is demand for a TB diagnostic that
is suitable for low-resource clinical settings and that can be easily integrated into clinical practice.
This paper reports the use of a glycan-functionalized magnetic nanoparticle-based colorimetric
biosensing assay (NCBA) that can be used to capture and increase the AFB count in PTB positive
sputum samples without the use of expensive and temperature-sensitive antibodies. The advantages
of the assay include: (1) Room-temperature assay, (2) no need for a power supply, (3) no refrigeration,
(4) affordable ($0.10/test), (5) rapid (<20 min), and (6) simple to implement. Using only a simple
magnet, the glycan-functionalized magnetic nanoparticles (GMNPs) function as an extractor and
concentrator of AFB without the need for an electrically powered centrifuge. No antibodies, aptamers
or peptides are required. Once the GMNP-AFB complex is formed, GMNPs facilitate rapid detection
due to the presence of visually observable clumped red-stained bacilli which are surrounded by brown
nanoparticles. This technique could be easily integrated into conventional TB control programs in
any resource-limited setting and where SSM has low sensitivity performance [15–23]. The assay
relies on the physical (magnetic) and chemical (glycan) properties of the nanoparticles to concentrate
mycobacteria cells from clinical samples. The acid-fast property of mycobacterial cells allow the color
change from gray to red. Specifically, acid-fastness is a staining property shared by mycobacterial
species which possess on their cell wall surface the presence of complex branched-chain hydroxy lipids
termed mycolic acids, or mycolates. In the acid-fast stain, the carboxylic acid group of the mycolic
acid reacts with the fuchsin dye. Subsequent application of a decolorizer will remove fuchsin from
the cell walls of non-mycobacteria, but not in mycobacteria. Thus, red clumps surrounded by brown
particles would indicate the presence of a mycobacterial species, hence the name “nanoparticle-based
colorimetric biosensing assay” (NCBA).
2. Materials and Methods
2.1. Chemicals and Reagents
N-acetyl-L-cysteine (NALC) and sodium hydroxide (NaOH) were purchased from Sigma-Aldrich
(St. Louis, MO, USA). The NaOH (0.4%) and NALC (0.025%, 1%, 2% and 4%) were prepared in distilled
water. A phosphate buffer saline solution (0.01 M PBS) was prepared using standard protocols. Carbol
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fuchsin, 0.3%, was prepared by dissolving 50 g of phenol in 100 mL 90% ethanol and adding 3 g of
basic fuchsin in the mixture which was brought to 1 L by adding distilled water. The decolorization
solution was 25% sulphuric acid. The counter stain was 0.3% methylene blue. GMNPs were provided
by the Alocilja Research Group from Michigan State University (USA). Briefly, GMNP (100 ± 58 nm)
has a magnetite (Fe3O4) core and a glycan (chitosan) coating. Fe3O4 was synthesized using ferric
chloride hexahydrate (FeCl3·6H2O) as a precursor in a mixture of ethylene glycol (as a reducing
agent) and sodium acetate (as a porogen). Chitosan was polymerized to surface-modify the iron
oxide nanoparticles.
2.2. Clinical Samples
Twenty-four left-over sputum samples collected from an equal number of patients diagnosed
with PTB were used, collected from the Mycobacteriology Laboratory, TB Prevention and Control
Program for the Highlands region of Chiapas, Mexico (Ministry of Health). Sputum samples (at least
1 mL) were used prior to the initiation of the anti-TB therapy. All information relating to the patients
was removed and the samples were decoded prior to their handling and processing. The samples were
either processed immediately on arrival at the laboratory or stored for less than 24 h at 4 ◦C before
processing. The samples were weighed with the assumption that 1 g equals 1 mL.
2.3. Optimization of Digestion Reagent
Twelve of the 24 sputum samples were used to optimize digestion-decontamination. Various
concentrations of NaOH and NALC were evaluated to liquefy and homogenize the samples without
negatively affecting the extraction ability of GMNP. Based on previous studies in the lab (unpublished
data), 0.4% NaOH was optimum and was used with different concentrations of NALC (0.025–4%) in
a 1:1 ratio to liquefy and homogenize the samples. The digestion time was monitored.
2.4. NCBA versus SSM
The NCBA approach was compared with the SSM method. Liquefied sputum samples were
separated into two portions, one for SSM and the other for the NCBA experiments. Figure 1 shows
a schematic of the SSM and NCBA approaches. The NCBA approach has two additional steps
compared with SSM: The addition of GMNP to the liquefied sputum sample and magnetic separation.
Unless GMNP concentration was the variable, 10 mg/mL of GMNP was used.
2.5. Sputum Smear Microscopy (SSM)
A smear was prepared from the first portion of the sample using the SSM method following
the standard protocol [3,24]. Briefly, 20 µL of the sputum sample was placed on a microscope slide
(~400 mm2) and heat fixed by passing flame from a Bunsen burner under the slide. The slide was
then placed on a staining rack and 0.3% carbol-fuchsin was poured over the smear. The underside of
the slide was gently heated by passing a flame under the rack until fumes appeared. After cooling
(~2 min), the smear was rinsed with distilled water until no color appeared in the effluent, followed by
washing with 25% sulphuric acid several times until the smear appeared light pink. The smear was
washed with distilled water and then 0.3% methylene blue was added to cover the smear. Distilled
water was used to wash off the counter stain and then the smear was air-dried. Once ready, the smear
was examined under a bright field microscope (Eclipse E400, Nikon Instruments Inc., NY, USA) using
a 100× oil immersion objective to observe the presence of red-colored AFB.
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Figure 1. Schematic representation of sputum smear microscopy (SSM) (top) and nanoparticle-based 
colorimetric biosensing assay (NCBA) (bottom) approaches. 
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temperature. The tube was then placed in a magnetic rack to separate the magnetic GMNP-AFB 
complex and the supernatant was discarded. The GMNP-AFB complexes were then washed and re-
suspended in 0.5 mL of 0.01 M PBS. A smear was prepared by transferring 20 µL of the liquefied 
sputum sample onto a microscope slide which was processed similar to the SSM method, where it 
was then examined under a bright field microscope to observe the presence of any clumped red-
colored AFB surrounded by brown nanoparticles. 
2.7. Optimization of GMNP Concentration 
In nine out of the 24 sputum samples, GMNP was added at three different concentrations (0.5, 
10, and 20 mg/mL) to determine the best concentration for the capture, extraction, concentration and 
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2.6. NCBA Approach
About 1 mL of the second portion of the sample was added into a 1.5 mL tube containing 0.5
mL of GMNP solution. The GMNP and sputum were mixed and allowed to incubate for 10 min at
room temperature. The tube was then placed in a magnetic rack to separate the magnetic GMNP-AFB
complex and the supernatant was discarded. The GMNP-AFB complexes were then washed and
re-suspended in 0.5 mL of 0.01 M PBS. A smear was prepared by transferring 20 µL of the liquefied
sputum sample onto a microscope slide which was processed similar to the SSM method, where it was
then examined under a bright field microscope to observe the presence of any clumped red-colored
AFB surrounded by brown nanoparticles.
2.7. Optimization of GMNP Concentration
In nine out of the 24 sputum samples, GMNP was added at three different concentrations (0.5, 10,
and 20 mg/mL) to determine the best concentration for the capture, extraction, concentration and
detection of AFB in the sputum samples. The subsequent procedure followed the NCBA approach
which was described above. To homogenize the sputum sample, 0.4% NaOH/1% NALC was added.
The time for magnetic separation was also determined.
2.8. Validation of the Optimized Parameters
Based on the optimization results, the remaining three of the 24 samples were used to validate
0.4% NaOH/4% NALC for digestion and 10 mg/ml GMNP for extraction.
2.9. Quantification of the AFB Count
The slides were mounted on a bright field optical microscope (Nikon Eclipse E400 Instruments Inc.)
and examined under oil immersion (100×). One hundred microscopy fields were observed to quantify
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the number of AFB present in each slide, for both SSM and NCBA, and all samples per treatment of
NaOH/NALC were pooled for reporting and statistical analysis.
2.10. Data Analysis
Statistical analysis was performed using SPSS version 21 on pooled data for each treatment,
AFB counts per field and the total number of fields. Pair-wise student’s t-tests were performed to
compare AFB mean counts between SSM and NCBA, in determining the digestion-homogenization
treatment and the optimal GMNP concentration. Pearson’s correlation coefficient was determined to
evaluate the association between the time for homogenization and magnetic separation. To measure
the effect of the length of time for homogenization and magnetic separation on the number of AFB
observed in NCBA, a linear regression model was used. All analyses were calculated at a 95%
confidence interval (α = 0.05).
2.11. Capture Efficiency (CE) of GMNP for Mycobacterial Cells
To understand the dynamics of GMNP-AFB interaction, a supplemental study was conducted to
determine the CE of GMNP for mycobacteria. Based on previous preliminary studies (unpublished
data), 5 mg/mL of GMNP was used. Due to biosafety considerations, Mycobacterium smegmatis (Msm)
was used as a surrogate for Mtb in the CE experiments. Msm shares a similar cell wall structure with
Mtb, both are AFB species, and both can be stained using the ZN technique [25,26]. Artificial sputum
was prepared following the polyacrylamide-based artificial sputum method [27]. A Msm culture was
grown in a MiddleBrook 7H9-ADC broth and incubated until the optical density reached 0.6 at 600 nm
(about log phase). Serial dilutions of the Msm bacteria were prepared and spiked into the artificial
sputum, followed by incubation for 10 min at room temperature along with manual shaking. The
GMNP-Msm complexes were magnetically separated using a simple magnetic rack and the supernatant
was removed. The complexes were washed twice and re-suspended in 0.5 mL of 0.01 M PBS. The
separated complexes along with pure bacterial dilutions were plated on a MiddleBrook 7H10-ADC
agar and incubated for seven days to allow the growth of Msm cells. The CE was determined as the
logarithm of cells captured divided by the logarithm of cells in the original dilution, as in Equation (1):
CE =
log(cell count o f cells captured)
log(cell count of cells in original dilution)
(1)
2.12. Transmission Electron Microscope (TEM) Imaging
GMNP-Msm complexes captured according to the previous section were visualized using a JEOL
100 CX transmission electron microscopy (TEM) at the MSU Center for Advanced Microscopy with
a magnification range of 5000× to 80,000×.
2.13. Ethics
Human subjects: Informed consent for participation was obtained from the patients and ethical
approval was obtained from the Research Committee at ECOSUR (CEI-O-47/14) as well as from the
Ministry of Health for Chiapas (5003/5342), under the project “Testing and evaluating a low-cost,
field-operable biosensor for rapid detection of pulmonary tuberculosis”. Sputum samples were
used only for the purpose of this study and the remaining samples were disposed according to
biosafety guidelines.
3. Results
3.1. Effect of NaOH-NALC Treatments on AFB Count
The role of NaOH is to eliminate the normal upper respiratory tract flora and the role of NALC is
to break down the disulfide bonds in mucin so that the sputum is liquefied and the AFB are released
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during the assay. The AFB count using NCBA increased to 35% with 1% NALC, followed by 22% with
2% NALC, and finally by 143% with 4% NALC (1216, 9353, and 7682, respectively, Table 1) for the
same number of fields counted compared to SSM (903, 7677, and 3160, respectively) for pooled data of
300 fields for each treatment (three samples per treatment, total of 12 samples). NALC at 4% produced
the highest AFB count.
Table 1. Optimization of N-acetyl-L-cysteine (NALC) treatment.
Concentration of NALC Solution Number of AFB by SSM Number of AFB by NCBA No. Fields Observed % Increase (NCBA-SSM)
0.025% 6525 3958 300 −39%
1% 903 1216 300 35%
2% 7677 9353 300 22%
4% 3160 7682 300 143%
Abbreviations: AFB, acid-fast bacilli; SSM, sputum smear microscopy; NCBA, nanoparticle-based colorimetric
biosensing assay.
3.2. Effect of GMNP Concentration on AFB Count
For the samples tested, GMNP at 10 mg/mL was the best concentration, with an AFB count
of 2575 compared to the SSM with 1958 (an increase of 32% using NCBA). For 20 mg/mL GMNP,
significant agglomerations were observed on the smear slides that affected the ability to clearly count
the cells. GMNP at 0.5 mg/mL had a negative effect on the AFB count for NCBA, potentially due to
reduced magnetic extraction effect while increasing the drag factor (Table 2).
Table 2. Optimization of the glycan-functionalized magnetic nanoparticles (GMNP) concentration.
Concentration of GMNP Number of AFB by SSM Number of AFB by NCBA No. Fields Observed % Increase (NCBA-SSM)
0.5 mg/mL MNP 876 391 300 −55%
10 mg/mL MNP 1958 2575 300 32%
20 mg/mL MNP 3979 5169 300 30%
Abbreviations: AFB, acid-fast bacilli; SSM, sputum smear microscopy; NCBA, nanoparticle-based colorimetric
biosensing assay.
3.3. Validation of the Optimized Parameters
Based on the optimization results (Tables 1 and 2), the optimized treatment was 0.4% NaOH/4%
NALC in a 1:1 ratio and 10 mg/mL of GMNP. Figure 2 shows that by using the optimized parameters,
the AFB count for SSM was 4059 and NCBA was 5977, increasing NCBA by 47%, showing the
extraction and concentration effect. The clinical relevance of this result is that an AFB count below
5000 in SSM would be considered a paucibacillary case and would likely lead to a false negative result
in conventional settings, increasing the risk of TB transmission. With NCBA, the AFB count is close to
6000, increasing the chance of a positive result and getting treatment, thus minimizing transmission
while increasing TB control.
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3.4. Effect of NCBA in Grading Smears
Each of the 24 samples was graded according to standard guidelines by a trained microscopist:
Seven were graded as 1+ and 17 were graded as 3+ (Table 3). The pooled AFB count for 1+ was 685
and 977 for SSM and NCBA, respectively, showing a gain of 43% by NCBA. The pooled AFB count for
3+ was 28,504 and 35,344 for SSM and NCBA, respectively, showing a gain of 24% by NCBA. Table 3
shows that 1+ would upgrade to 2+ using the NCBA. The equivalent AFB count per mL (20 µL of
sample on 100 fields) was calculated and is also presented in Table 3. This result is impactful as there
are many clinical cases of low bacillary counts (paucibacillary).
Table 3. Acid-fast bacilli (AFB) count analysis of the graded samples.
1+ Grade a 2+ Grade a 3+ Grade a
SSM, Total AFB counts 685 28,504
NCBA, Total AFB counts 977 35,344
No. Fields 700 1700
Percent increase by NCBA 43% 24%
SSM, AFB per 100 HPF 98 1677
NCBA, AFB per 100 HPF 140 140 2079
SSM, AFB/mL 4.9 × 103 8.4 × 104
NCBA, AFB/mL 7.0 × 103 1.0 × 105
Abbreviations: SSM, sputum smear microscopy; NCBA, nanoparticle-based colorimetric biosensing assay; HPF,
high power fields. a Based on WHO and IUATLD grading scale: Negative (0 AFB/100 HPF); Scanty (1–9 AFB/100
HPF); 1+ (10–99 AFB/100 HPF); 2+ (100–9900 AFB/100 HPF on average); 3+ (>10,000 AFB/100 HPF on average).
Figure 3 shows images of stained AFB slides for SSM and NCBA on sputum samples graded
as 1+, 2+, and 3+, according o the guidelines by the WHO and IUATLD [24]. There is an obvious
concentration effect using NCBA (Figure 3A) compared with SSM (Figure 3B) and also a higher
AFB count in NCBA, compared to SSM. In some fields, the number of AFB observed in NCBA were
highly clustered.
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Figure 3. Images of AFB cells on smear slides for NCBA (A) and SSM (B). AFB appear dark red,
surrounded by brown nanoparticles in NCBA. Representative images of sputum samples graded
as 1+, 2+, and 3+ are shown. There is an obvious agglomeration of GMNP-AFB in the NCBA.
The blue background comes from the methylene blue that is added during the assay to decolorize
non-mycobacterial cells.
SSM positivity and grade indicate relative bacterial load, associated disease presentation, and
infectivity for patients with TB according to the guidelines by the International Union Against
Tuberculo is nd Lung Diseas (IUATLD) and the World H alth Organization (WHO). The grade
is either 3+, 2+, 1+, scanty negative, acco ding to th number of AFB pres nt in one undred
microscopic fields. A single sputum s mple must have between 5000–10,000 cells per L for reliable
TB detection; below thi concentration, SSM might give either negative or unc rtain result.
3.5. Effect of Homogenization and Magnetic Separation on AFB Count
Statistical analyses were conducted to assess whether the sample volume, time for homogenization
and time for magnetic separation influenced AFB count in the NCBA. The results showed that there was
no association between the sample volume and the mean time of homogenization (Pearson’s correlation,
−0.016; p = 0.42), implying that sample volume did not affect homogenization time. However, the
mean time for homogenization and magnetic separation were correlated (Pearson’s correlation, 0.643;
p < 0.001). The longer it took to homogenize the sample, the more time was needed to magnetically
separate the GMNP-AFB complex from the rest of the sputum matrix. It was also found that a longer
period of homogenization resulted in higher AFB counts, while longer magnetic separation time
decreased the number of AFB observed per field in NCBA (Global correlation coefficient, 0.187,
p < 0.001). The long homogenization t m s are likely due to the h gh mucopurulence of the sputu
samples, which is lated to high viscosity and high cellula load. Highly viscous samp s educe the
mobility of GMNPs in the matrix and the formation of GMNP-AFB complexes, which can have a
influence on their magnetic separation.
3.6. Supplementary Study Using Msm
Figure 4A shows the capture efficiency (CE) of the GMNP in different concentrations of Msm.
These were prepared in artificial sputum, magnetically extracted and plated on a MiddleBrook
7H10-ADC agar. The data shows that the CE decreases linearly with increasing bacterial concentration,
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from 95% at 101 CFU/mL to 80% at 105 CFU/mL. This result supports the sputum data in Table 3,
where 1+ samples transform to 2+ using NCBA, since a lower bacterial concentration would result in
a higher CE. Figure 4 also shows TEM images of corded Msm without GMNP (B) and with GMNP (C).Biosensors 2018, 8, x FOR PEER REVIEW  9 of 13 
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4. Discussion
SSM continues to be the main TB diagnostic method in medium and low income countries due to
its affordability, simplicity in process and rapid results. However, its sensitivity ranges from 20–80%,
mainly due to the high AFB cell concentration that is required (5000–10,000 cells/mL). Different
chemical and physical sputum processing methods have been studied to improve its sensitivity,
but standardization of the treated samples is among major drawbacks [28]. The use of antibodies
and peptides for bacterial extraction in a matrix is a common practice. In a study by Foddai et
al. [29], magnetic beads coated with specific peptides yielded an 85–100% CE when used to separate
Mycobacterium avium subsp. paratuberculosis from broth samples containing 103–104 cfu/mL of the
bacteria. Roberts and Hirst [30] used antibodies against Mycobacterium ulcerans to isolate the bacteria
and yielded a 70–85% CE.
Studies evaluating nanoparticles synthesized with diverse materials have used spiked
sputum samples from healthy donors and sophisticated equipment to detect whole mycobacterial
cells [12,31–33]. Those studies have reported good detection of mycobacteria, but the assays are
complex and expensive.
Sputum is a complex specimen consisting of linked mucin molecules, filamentous actin, cell
debris, DNA, leukocytes, proteoglycans, inflammatory mediators and elastin fibers [34]. Embedded
within this matrix are bacteria including Mtb in TB+ sputum. Mtb cells clump due to cording within the
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specimen, resulting in an unequal distribution. The efficient release of bacteria from sputum specimens
requires a chemical and/or mechanical breakdown of the linked mucin and actin molecules [30].
For this study, a combination of NaOH (0.4%) and NALC (0.025–4%) in a 1:1 ratio was explored for use
in sputum digestion. The rationale for testing low and high concentrations of NALC was to determine
if the solution would affect the overall performance of NCBA. Higher NALC concentration results
in better liquefaction of the sputum and subsequently better extraction of AFB, however, that would
also mean a higher cost since NALC is expensive. The assay is designed as a low-cost system for
application in resource-limited environments. The results show that 0.4% NaOH/4% NALC yielded
the best performance, as indicated by the higher AFB count in NCBA, with an overall 143% increase
over SSM (Table 1). At a lower concentration of NALC (0.025%), SSM resulted in higher AFB counts
compared to NCBA, potentially due to the sputum not being fully liquefied and the GMNP-AFB
complexes not being able to be released from the clumped matrix.
The use of a glycan bioreceptor on GMNP allows for simple and inexpensive capture of Mtb
cells in the mucoid sputum samples without the use of expensive antibodies or aptamers. The Mtb
cell envelope is particularly rich in complex carbohydrate-containing molecules, such as glycolipids
(e.g., phosphatidyl-myo-inositol mannosides), lipoglycans (e.g., lipomannan and lipoarabinomannan),
polysaccharides (e.g., α-glucan) and glycoproteins. These mycobacterial carbohydrate molecules can
bind with the glycan functionalized nanoparticles. Furthermore, cold storage is not required, allowing
its application in conditions without refrigeration and electricity.
GMNP at 10 mg/mL was found to be the optimal amount to capture and concentrate AFB which
resulted in the highest AFB count per field (Table 2, Figure 3). At a higher GMNP concentration
(20 mg/mL), smears were difficult to observe due to high aggregation.
NALC at 1% and 2% resulted in 35% and 22% increases in AFB count, respectively. NALC at 4%
resulted in a 143% increase in AFB count. If an input/output ratio is calculated, that is, %NALC/%AFB
increase, 1/35 and 4/143 each equals to 0.028 while 2/22 equals to 0.09. This shows that increasing
NALC concentration to homogenize the sputum sample correspondingly increases the AFB count,
except for the 2% NALC that is more of an outlier. The experiments used 4% NALC as the upper value
to minimize cost. It would be interesting to determine in future experiments the upper limit of NALC.
Also, longer homogenization time was correlated with longer magnetic separation. This could
be due to the viscosity of the sputum which would then slow down the magnetic separation.
Long magnetic separation had a negative effect on the AFB count. The longer the magnetic separation,
the longer the exposure of AFB to the NaOH/NALC homogenization solution, which would then
increase the exposure of the sample to the decontamination effect of NaOH, subsequently reducing the
viability of the AFB.
Determining GMNP’s Capture Efficiency for Mycobacterial Cells
Results from the GMNP extraction experiments using Msm showed that the CE ranged from
an average of 80% to 95% for samples with AFB concentrations ranging from 101 cfu/mL (n = 3)
to 103 cfu/mL and 104 cfu/mL (n = 10 each) (Figure 4A). The negative linear relationship between
bacterial cell concentration and the CE indicates that NCBA would be highly useful in cases of
low bacterial load, as in paucibacillary cases. These data show that as cells increase, CE decreases,
potentially due to epitope competition. The lower the number of bacteria in the solution, the higher
the ratio of nanoparticles is to bacterial epitopes, that is, more nanoparticles are available to bind and
self-assemble on the surface of a bacterium. As the number of bacteria in the solution increases, the
resulting higher number of bacterial epitopes compete with the available number of nanoparticles in
the solution. Such a nanoparticle-based bacterial detection system would be highly sensitive at lower
cell concentrations.
The physical interaction between GMNP and the Msm cell wall was also confirmed using TEM
(Figure 4B,C). GMNPs attach to specific sites on the cellular surface through the carbohydrate-binding
Biosensors 2018, 8, 128 11 of 13
lectins on the bacterial surface. These data show that the GMNP interacts with the mycobacterial cell
wall, forming a complex.
5. Conclusions
In summary, these results show that the NCBA technique has significant potential application in
improving the diagnosis of paucibacillary TB cases (e.g., in immunocompromised individuals, children,
drug-resistant TB, among others). Due to its ability to concentrate AFB, NCBA could improve one
grade higher, making an initial case at 1+ to become 2+ with the assay, or go from “scant” to become 1+
(Table 3). The assay uses only a simple magnet and does not require any major equipment, electricity or
refrigeration, can be completed in 10–20 min and only costs $0.10 per test. The glycan-based magnetic
isolation method is novel and has advantages due to its affordability, long shelf-life, room-temperature
storage and easy preparation. Thus, this system can be easily incorporated in clinical practice to
enhance TB diagnosis, especially in low resource environments. It has been hypothesized that a rapid
and universally accessible TB test with a sensitivity of 85% and specificity of 97% has the potential
to save close to 400,000 adjusted lives annually, or 27% of the global TB deaths [35]. This NCBA
technology satisfies the criteria well for rapid, affordable and universal access.
Future work will include determining the limit of detection (LOD) and comparing NCBA with
cultures on solid media (7H11 Middlebrook), leading to sensitivity evaluation in paucibacillary cases.
The assay will also use blinded samples in comparison with SSM, not only in sputum samples, but also
in gastric samples from pediatric patients.
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